Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.37 |
| ▸ | GABRE | P78334 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31390521 | 1.00 | MAPK1 (0.47) | MAPK1SIRT6KDM4EL3MBTL1LOXL2 | |
| Hydrochloric Acid SCHEMBL1566955 | 0.98 | MAPK1 (0.46) | MAPK1SIRT6KDM4EL3MBTL1LOXL2 | |
| SCHEMBL12844583 | 0.84 | MAPK1 (0.49) | MAPK1SIRT6KDM4EL3MBTL1LCK | |
| SCHEMBL991320 | 0.84 | MAPK1 (0.49) | MAPK1SIRT6KDM4EL3MBTL1LCK | |
| SCHEMBL12184767 | 0.83 | POLB (0.46) | KDM4EL3MBTL1POLBGABRPGABRD | |
| SCHEMBL30445565 | 0.83 | POLB (0.46) | KDM4EL3MBTL1POLBGABRPGABRD | |
| SCHEMBL68869 | 0.82 | MAPK1 (0.63) | MAPK1SIRT6KDM4EL3MBTL1LCK | |
| SCHEMBL11030074 | 0.82 | MAPK1 (0.47) | MAPK1SIRT6KDM4EL3MBTL1LCK | |
| SCHEMBL31390501 | 0.82 | MAPK1 (0.47) | MAPK1SIRT6KDM4EL3MBTL1LCK | |
| SCHEMBL6917612 | 0.82 | MAPK1 (0.47) | MAPK1SIRT6KDM4EL3MBTL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025041160-A1 | BIFUNCTIONAL CONJUGATE MOLECULES FOR CANCER TREATMENT AND PROCESS OF MAKING THE SAME | BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE (BITS), PILANI (IN) | 2025-02-27 | — | — | WO | disclosed |
| US-10870624-B2 | Histone deacetylase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20180170876-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| US-20180170876-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| US-9963434-B2 | N-arylmethyl sulfonamide negative modulators of NR2A | LUC THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963434-B2 | N-arylmethyl sulfonamide negative modulators of NR2A | LUC THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| WO-2015048503-A2 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | GRIN2A, GRIN2B, NR2C2 | MAPK1 3620/4885SIRT6 2442/4885KDM4E 2241/4885 |
| US-20180170876-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC11 | MAPK1 1092/4885SIRT6 66/4885KDM4E 146/4885 |
| US-10870624-B2 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC2 | MAPK1 1905/4885SIRT6 66/4885KDM4E 133/4885 |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | GRIN2A, GRIN2B, NR2C2 | MAPK1 3620/4885SIRT6 2442/4885KDM4E 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.